Media & Investor Relations
The Company: Epeius Biotechnologies Corporation is a privately held specialty biopharmaceutical company whose mission is to develop and commercialize its proprietary targeting technologies.
The Platform: The Epeius Targeted Delivery System (TDS) - enables stealth nanoparticles to be injected directly into a vein to deliver therapeutic genes selectively to cancerous lesions.
The Market: Treatment of metastatic cancer and all solid tumors - TDS-targeted cancer therapeutics are more effective and less toxic than conventional medicines and chemotherapy.
Business Strategy
Driven by the outstanding potential of its TDS targeting technologies to revolutionize medical delivery and cancer therapy, Epeius Biotechnologies Corporation is well positioned to continue to lead by example with the development of its strategic business plan:
- from the pursuit of excellence and innovation demonstrated by its scientific founders who transitioned successfully from academic leaders into visionary business builders,
- to the fast track development, GMP manufacturing, market validation, and commercialization of its lead product Rexin-G™,
- to the establishment of a diversified revenue model based on the pioneering designs, proprietary molecular engineering, strong clinical performance, and urgent medical need for the world's first and finest targeted genetic medicine.
Orderly execution of the business plan calls for the progressive recruitment of an executive management team, knowledgeable value-added investors, and strategic alliances that will serve to accelerate corporate growth, provide market savvy, and conserve capital. Development of the diversified revenue model calls for effective management of a high-value product franchise, continued development of intellectual properties, and economies of manufacturing scale-up, as well as product marketing, distribution, and out-licensing of TDS platform technologies. Ultimately, we anticipate that Epeius Biotechnologies will continue to accelerate in terms of product demand, market penetration, and revenue growth.
Business Execution
Epeius Biotechnologies Corporation has secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Rexin-G™, to seek and destroy metastatic tumors. Following the success of its initial "compassionate use" clinical trials of Rexin-G™, Epeius Biotechnologies has completed the transition from an academic startup to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States. In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that "we are now in excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide."
